KKR-backed Gamma Biosciences, a life sciences tools platform, agreed to acquire a majority stake in Mirus Bio, a biotechnology company. Financial terms were not disclosed. "Mirus brings decades of experience in transfection and cell engineering and a portfolio of best-in-class transfection products for in vitro and in vivo delivery, adding a new foundational platform that complements Gamma's existing offering in advanced therapy manufacturing," Matt Gunnison, Gamma Biosciences President.